Literature DB >> 3234639

Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats.

F Sodoyez-Goffaux1, J C Sodoyez, M Koch, C J De Vos, B H Frank.   

Abstract

Insulin, biosynthetic human proinsulin and 2 human proinsulin conversion intermediates, des (64, 65) human proinsulin and des (31, 32) human proinsulin, were labelled with 123 I and the derivatives monosubstituted on Tyr A14 were purified by reverse phase high performance liquid chromatography. The four tracers were injected into anaesthetized rats via a jugular or a portal vein and time activity curves were generated for the liver and kidneys using a gamma camera and an online computer. Liver extraction coefficients varied in the order insulin (38%), des (64, 65) human proinsulin (11.7%), des (31, 32) human proinsulin (3.2%), human proinsulin (1.6%); whereas half-life of hepatic activity varied in the reverse order, from 6 min for insulin, to 45 min for human proinsulin. As expected for a non-receptor mediated process, kidney extraction varied conversely to liver extraction, being highest for human proinsulin and lowest for insulin. It is concluded that the kinetics of human proinsulin conversion intermediates depends upon the site of cleavage and deletion and is intermediate between those of insulin and intact human proinsulin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234639     DOI: 10.1007/bf00277489

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Plasma proinsulin in patients with functioning pancreatic islet cell tumors.

Authors:  B M Sherman; S Pek; S S Fajans; J C Floyd; J W Conn
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

2.  The interactions of proinsulin with insulin receptors on the plasma membrane of the liver.

Authors:  P Freychet
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

3.  In vitro studies of the rate of proinsulin and insulin turnover in seven human insulinomas.

Authors:  C Creutzfeldt; N S Track; W Creutzfeldt
Journal:  Eur J Clin Invest       Date:  1973-09       Impact factor: 4.686

4.  The handling of insulin, proinsulin, and C-peptide by the isolated rat kidney.

Authors:  R Rabkin; B D Ross; M E Mako; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

5.  Familial hyperproinsulinemia: partial characterization of circulating proinsulin-like material.

Authors:  K H Gabbay; R M Bergenstal; J Wolff; M E Mako; A H Rubenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Visualization of viral clearance in the living animal.

Authors:  E M Verdin; E Maratos-Flier; C R Kahn; J C Sodoyez; F Sodoyez-Goffaux; C J De Vos; S P Lynn; B N Fields
Journal:  Science       Date:  1987-04-24       Impact factor: 47.728

7.  Evidence for separate handling in vivo of different regions of the insulin molecule using A14- and B1-labeled insulin tracers.

Authors:  C S Cockram; R H Jones; M A Boroujerdi; P H Sönksen
Journal:  Diabetes       Date:  1984-08       Impact factor: 9.461

8.  Characterization of proinsulin-insulin intermediates in human plasma.

Authors:  C de Haën; S A Little; J M May; R H Williams
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

9.  Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance.

Authors:  E Ferrannini; A Pilo
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  1 in total

Review 1.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.